Royal Bank of Canada’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Royal Bank of Canada’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-700	Closed	-$34K	–	7187
2020 Q1	$34K	Sell	700 -59,262	-99%	-$2.76M	﹤0.01%	5330
2019 Q4	$2.81M	Buy	59,962 +59,262	+8,466%	+$2.62M	﹤0.01%	2578
2019 Q3	$17K	Sell	700 -5	-0.7%	-$148	﹤0.01%	5580
2019 Q2	$21K	Buy	705 +5	+0.7%	+$115	﹤0.01%	5706
2019 Q1	$16K	Sell	700 -3	-0.4%	-$64	﹤0.01%	5778
2018 Q4	$13K	Sell	703 -159	-18%	-$2.5K	﹤0.01%	5779
2018 Q3	$16K	Buy	862 +846	+5,288%	+$10K	﹤0.01%	5801
2018 Q2	$0	Buy	16 +9	+129%	+$62	﹤0.01%	6932
2018 Q1	$0	Buy	+7	New	+$50	﹤0.01%	7049
2017 Q4	–	Sell	-1,069	Closed	-$16K	–	7126
2017 Q3	$16K	Buy	+1,069	New	+$16.2K	﹤0.01%	6088
2017 Q2	–	Sell	-222	Closed	-$5K	–	6932
2017 Q1	$5K	Sell	222 -273	-55%	-$5.22K	﹤0.01%	6238
2016 Q4	$8K	Buy	+495	New	+$6.73K	﹤0.01%	6176

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Royal Bank of Canada's RARX Position: Q2 2020 in Review

Royal Bank of Canada sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 700 shares — an estimated $34K sold.

Royal Bank of Canada first reported a position in RARX in Q4 2016 and held it in 12 quarters. The position peaked at $2.81M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Royal Bank of Canada reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Royal Bank of Canada sold 700 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $34K.
Royal Bank of Canada first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 12 quarters.
Royal Bank of Canada's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.81M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Royal Bank of Canada's 13F filing for Q2 2020, filed 14 Aug 2020.